Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Page 1 de 31 résultats
.beta.-alanine derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The invention relates to .beta.-alanine derivatives of the formula I ##STR2##
in which Q.sub.1, Q.sub.2, Q.sub.3 or Q.sub.4 is, in each case, independently of one another, CH or N, R.sup.1 is H, A, Ar, Hal, OH, OA, CF.sub.3 or OCF.sub.3, R.sup.2 is H or A, ##STR3## R.sup.4 and R.sup.5 are, in each
3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to certain 3-(heteroaryl)alanine derivatives which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
References
The following publications, patents and patent applications are cited in this
3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to certain 3-(heteroaryl)alanine derivatives which inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4.
REFERENCES
The following publications, patents and patent applications are cited in this
Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as
Manganese superoxide dismutase Val16Ala polymorphism predicts resistance to chemotherapeutic drug cancer therapy
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable
BACKGROUND OF THE INVENTION
Cancer is the second leading cause of death behind heart disease. In fact, cancer incidence and death figures account for about 10% of the U.S. population in certain
Composition for preventing or treating liver cancer containing ginsenoside F2
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This application claims the benefit of Korean Patent Application No 10-2016-0099978, filed Aug. 5, 2016, the entirety of which is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for preventing or treating liver cancer containing
Methods of treating cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD
This invention relates to methods of treating cancer in a subject in need thereof.
BACKGROUND
The expanding development and use of targeted therapies for cancer treatment reflects an increasing understanding of key oncogenic pathways, and how the targeted perturbation of these pathways
Composition and method for treating cancer and immunological disorders resulting in chronic conditions
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention is directed to a composition for treating early stages of various forms of malignancies, particularly melanoma and lung cancer, in mammals. In more advanced stages of malignancies, such as those involving larger tumors and/or metastases, the composition
Peptides for the treatment of cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/EP2014/050330 filed 9 Jan. 2014, which claims priority to European Patent Application No. 13150974.7 filed 11 Jan. 2013. The entire contents of each
Peptides for the treatment of cancer
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The present invention relates to an isolated peptide exhibiting antitumoral effects.
Every year millions of people are diagnosed with cancer worldwide. Notwithstanding in the last decades much progress has been achieved in cancer therapy, nevertheless cancer remains a leading cause of death.
Type polypeptide targeting tumours
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the national phase of International Application No. PCT/CN2016/100989, titled "A NEW TYPE POLYPEPTIDE TARGETING TUMOURS", which claims the priority of Chinese Patent Application No. 201510650649.2, filed on Oct. 10, 2015 with the State
Peptide agents for cancer therapy
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to agents for the inhibition of the growth and/or proliferation of cancer cells.
BACKGROUND OF THE INVENTION
Integrins comprise a family of cell adhesion receptors composed of alpha/beta heterodimeric subunits that provide a functional and structural
Camptothecin .beta.-alanine esters with topoisomerase I inhibition
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to .beta.-alanine esters of camptothecin compounds which inhibit the enzyme topoisomerase I and have anticancer activity. This invention is also related to the treatment of tumors in animals with camptothecin compounds.
2.
Labelled compound
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The present invention relates to a labelled compound and a method for manufacturing the compound. More particularly, the present invention relates to a compound labelled with radionuclide such as positron nuclide or stable isotope. The labelled compound of the invention is
Peptide derivatives
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to peptide derivatives exhibiting pharmaceutical activities such as analgesic activity through action on opioid receptors and the like.
BACKGROUND ART
The existence of opioid receptors to which opioids such as morphine bind was verified in the early
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
